-
The clinical utility of microvolt T-wave alternans (MWTA) testing to detect subtle beat-to-beat oscillations in the electrocardiogram's T-wave amplitude as a non-invasive method for predicting sudden cardiac death remains undetermined.
-
-
Individualization of therapy with pharmacogenetics; the rate vs rhythm debate; the FDA's Risk Evaluation and Mitigation Strategy; FDA actions.
-
Small studies with older equipment at single centers have shown that coronary CT angiography (CTA) is promising for evaluating coronary anatomy. New 64-slice CT scanners have improved spatial and temporal resolution. Thus, these investigators from the Netherlands conducted a prospective, multi-centered, multi-vendor study to assess the accuracy of 64-slice CTA for in dentifying significant coronary artery disease (CAD) in symptomatic patients undergoing conventional coronary angiography (CCA).
-
In this paper, stevenson et al, from 18 centers with expertise in ventricular tachycardia (VT) ablation, report the results of VT ablation using the Thermo°Cool-irrigated, tipped-radiofrequency ablation catheter. Patients were eligible for the study if they had multiple episodes of sustained monomorphic VT that had required either cardioversion or antiarrhythmic drug administration in the previous six months.
-
-
FDA warning on topical anesthetics; antipsychotics increase sudden cardiac death; the step up vs step down debate; treating pain, fatigue, mood, and sleep in fibromyalgia; FDA Actions.
-
The goal of treatment during ST elevation myocardial infarction (STEMI) is early reperfusion of the occluded coronary artery, as this has been shown to reduce mortality and morbidity.
-
Ray et al examined the computerized files of Tennessee Medicaid recipients to estimate the effects of atypical antipsychotic drugs on the risk of sudden cardiac death.
-
Nebivolol is a new beta 1 selective blocker with vasodilatation properties via activation of the L-arginine/nitric oxide pathway. Short-term studies, and a long-term, open-label study, have shown excellent efficacy and safety in stages 1-11 hypertension.
